MedTrace Logo

Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging

NCT03478917 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2023-07-17

No results posted yet for this study

Summary

Background:

Painful vasoocclusive crisis (VOC) occurs in people with sickle cell disease (SCD). People with VOC have many visits to the hospital. About 10 30 percent of these people will go on to develop acute chest syndrome (ACS). ACS can cause further ill health. It can also cause death. Researchers want to find ways to diagnose ACS more quickly. To do this, they want to use stored blood samples and scans from a study (the DeNOVO trial) that was closed in 2015. They want to see if scans and samples taken of people with VOC who later developed ACS could help diagnose ACS faster. The data of people in the DeNOVO study who did not develop ACS will serve as controls.

Objectives:

To look at data from the DeNOVO trial to find a way to diagnose ACS more quickly.

Eligibility:

People 10 85 years old who took part in NHLBI Protocol number 05-H-0019 (the DeNOVO trial). The trial lasted from 2004 to 2008. The study was closed in November 2015.

Design:

Scans and intact, frozen samples from a study that was closed in 2015 will be studied. No new participants will be enrolled.

...

Conditions

  • Sickle Cell Disease (SCD)

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Arun S Shet, M.D. · National Heart, Lung, and Blood Institute (NHLBI)

Eligibility

Min Age
10 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2019-12-31
Completion
2021-10-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03478917 on ClinicalTrials.gov